Dose constraints for moderate hypofractionated radiotherapy for prostate cancer The French genito-urinary group (GETUG) recommendations

Autor: Gilles Créhange, C Llagostera, C Bonin, S. Belhomme, P. Sargos, R. de Crevoisier, Caroline Lafond, Christophe Hennequin, G. Delaroche, J Langrand-Escure, David Pasquier, Stéphane Supiot, I. Latorzeff, F Bideault
Přispěvatelé: Laboratoire Traitement du Signal et de l'Image (LTSI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), CRLCC René Gauducheau, Département de radiothérapie, CRLCC Val d'Aurelle - Paul Lamarque, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Institut Bergonié [Bordeaux], Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lille-UNICANCER, Institut de Cancérologie Lucien Neuwirth, CHU Saint-Etienne, Service de radiothérapie, CRLCC Eugène Marquis (CRLCC), UNICANCER-Université Lille Nord de France (COMUE), Centre de Recherche en Informatique, Signal et Automatique de Lille - UMR 9189 (CRIStAL), Ecole Centrale de Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Clinique Pasteur [Toulouse], Département de Radiothérapie, Centre René Gauducheau-Centre de Lutte Contre le Cancer Nantes Atlantique 'René Gauducheau' (CLCC)-Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Hypofractionated Radiotherapy
Male
Organs at Risk
medicine.medical_specialty
[SDV]Life Sciences [q-bio]
medicine.medical_treatment
Urinary system
030232 urology & nephrology
Planning target volume
[SDV.CAN]Life Sciences [q-bio]/Cancer
Recommendations
Dose constraints
03 medical and health sciences
Prostate cancer
0302 clinical medicine
medicine
Humans
Radiology
Nuclear Medicine and imaging
Image-guided radiation therapy
ComputingMilieux_MISCELLANEOUS
Radiotherapy
business.industry
Standard treatment
Radiotherapy Planning
Computer-Assisted
Prostatic Neoplasms
medicine.disease
Magnetic Resonance Imaging
3. Good health
Radiation therapy
Oncology
030220 oncology & carcinogenesis
Hypofractionation
Radiation Dose Hypofractionation
[SDV.IB]Life Sciences [q-bio]/Bioengineering
Radiology
France
Radiotherapy
Intensity-Modulated
business
Tomography
X-Ray Computed
Radiotherapy
Image-Guided
Zdroj: Cancer Radiothérapie
Cancer Radiothérapie, Elsevier Masson, 2018, 22 (2), pp.193-198. ⟨10.1016/j.canrad.2017.11.004⟩
Cancer/Radiothérapie
Cancer/Radiothérapie, 2018, 22 (2), pp.193-198. ⟨10.1016/j.canrad.2017.11.004⟩
Cancer Radiothérapie, Elsevier Masson, 2018, 22 (2), pp.193-198
ISSN: 1278-3218
1769-6658
Popis: International audience; Considering recent phase III trials results, moderate hypofractionated radiotherapy can be considered as a standard treatment for low and intermediate risk prostate cancer management. This assessment call for a framework allowing homogeneous and reproducible practices in the different centers using this radiotherapy schedule. The French Genito-Urinary Group (GETUG) provides here recommendations for daily practice of moderate hypofractionated radiotherapy for prostate cancer, with indications, dose, fractionation, pre-treatment planning, volume of interest delineation (target volume and organs at risk) and margins, dose constraints and radiotherapy techniques.
Databáze: OpenAIRE
Externí odkaz: